Xanomeline is a functionally selective M 1 /M 4 muscarinic acetylcholine receptor agonist that nevertheless binds with high affinity to all five subtypes of muscarinic receptors. A novel mode of interaction of this ligand with the muscarinic M 1 receptors characterized by persistent binding and receptor activation after extensive washout has been previously shown. In the present study, using human M 1 and M 2 receptors expressed in Chinese hamster ovary cells and 3 H-N-methylscopolamine as a tracer, we show that persistent binding of xanomeline also occurs at the M 2 receptor with similar affinity as at the M 1 receptor (K I = 294 and 296 nM, respectively). However, kinetics of formation of xanomeline wash-resistant binding to M 2 receptors were markedly slower than to M 1 receptors. Xanomeline was a potent fast-acting full agonist in stimulating guanosine-5'-
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Muscarinic acetylcholine receptors mediate a wide variety of physiological functions (Caulfield, 1993) . Five subtypes of muscarinic acetylcholine receptors have been cloned (Bonner et al., 1987) ; each is involved in mediating specific functions. For this reason subtype-selective muscarinic ligands with potential therapeutic use have been pursued for several decades. For example, M 1 receptors take part in cognitive processes and formation of memory. Many studies have documented that in the course of natural aging and particularly in Alzheimer's disease, there is marked loss of cholinergic neurons in basal forebrain and their terminals in the brain cortex and hippocampus (Perry et al., 1977a; 1977b; Bartus et al., 1982; Francis et al., 1999; Dolezal and Kasparova, 2003) .
This decrease in cholinergic input is not accompanied by changes in the density of postsynaptic M 1 receptors (Ladner and Lee, 1998) . Therefore, an agonist that works selectively at the M 1 muscarinic receptor might improve memory in Alzheimer's patients without eliciting serious side effects mediated by other muscarinic receptor subtypes.
However, the high homology among subtypes of muscarinic receptors in the transmembrane domain where the acetylcholine binding site is located makes the search for selective ligands difficult, with more success in discovering receptor antagonist than agonist ligands. To date, only a few selective agonists have been described. One of them is xanomeline (3-[3-hexyloxy-1,2,5-thiadiazo-4-yl]-1,2,5,6-tetrahydro-1-methylpyridine) that has been identified as a functionally selective potent agonist for M 1 and M 4 receptors (Shannon et al., 1994; Ward et al., 1995; Bymaster et al., 1997 Bymaster et al., , 1998 . Strikingly, despite its functional selectivity, no major differences in the affinity of xanomeline binding to individual subtypes of muscarinic receptors have been found (Bymaster et al., 1997;  MOL #23762 xanomeline therefore remains known.
A remarkable feature of xanomeline action is its ability to stimulate M 1 muscarinic receptors even after intensive washing to remove the free ligand (Christopoulos et al., 1998 (Christopoulos et al., , 1999 . It has been demonstrated that xanomeline binds to M 1 muscarinic receptors in two ways; reversibly to the orthosteric binding site where conventional muscarinic agonists and competitive antagonists bind, and firmly to another site that is close to but not identical to the orthosteric binding site. Binding of xanomeline to this ectopic site is resistant to washing and is accompanied by persistent receptor activation. It also modulates binding of ligands to the receptor's orthosteric site in a complex manner (Jakubik et al., 2002) . However, wash resistant binding of xanomeline as such cannot explain its functional selectivity because it is not confined to the M 1 receptor subtype. A similar mode of xanomeline binding to the M 5 receptor, for example, has recently been shown (Grant and El-Fakahany, 2005) . However, xanomeline avid binding in this case results in persistent antagonism of receptor activation by agonists.
The aim of our experiments was to get further insight into the basis of xanomeline mechanisms of action and functional selectivity. To this end we compared the mechanism of xanomeline binding to and activation of a pair of muscarinic receptors where xanomeline exhibits marked differential efficacy. We chose the M 1 receptor where xanomeline behaves as a potent and efficacious agonist, and the M 2 receptor where xanomeline binds equally well but does not result in receptor activation. M 1 receptors MOL #23762 6 preferentially couple to the G q / G 11 family of heterotrimeric G-proteins that lead to activation of phospholipase C, whereas M 2 receptors preferentially couple to the G i / G o family of G-proteins that result in inhibition of adenylyl cyclase (Caulfield, 1993) .
However, besides these principal G-proteins, muscarinic receptors also couple to some extent to other G-protein classes (Jakubik et al., 1996; Michal et al., 2001; Tucek et al., 2002) . Therefore, we examined xanomeline-induced receptor coupling to individual classes of G-proteins using the scintillation proximity assay (DeLapp et al., 1999) .
In this work we demonstrate that wash-resistant binding of xanomeline occurs at both the M 1 and M 2 subtypes of muscarinic receptors. However, there are marked differences in the kinetics of formation of wash-resistant xanomeline-receptor complex between these two receptor subtypes. There are also marked differences in the kinetics, potency and efficacy of activation of various G proteins by xanomeline at these receptors. These differences may contribute to the functional selectivity of this unique muscarinic receptor agonist.
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Treatment with xanomeline
Two types of experiments with xanomeline were carried out. In experiments referred to as "continuous presence" xanomeline was present during incubation with radioligands.
On the other hand, in experiments referred to as "prelabelling / washing" to determine xanomeline "wash-resistant binding" membranes were preincubated for 60 min at 30 ºC with the indicated concentrations of xanomeline, centrifuged for 30 min at 30,000 x g at 4°C, and resuspended in incubation medium. Centrifugation and resuspension was repeated three-times with a 30-min waiting period in between to ensure removal of free xanomeline in the medium. Alternatively, xanomeline was added to intact cells in case of measurement of kinetics of its binding or activation of [ 35 S]GTPγS ( Fig. 2 and 4 ) to expedite first steps of washing. Cells were treated with xanomeline at 30 ºC for the indicated times then centrifuged for 1 min at 300 x g. The medium was quickly removed then cells were resuspended in incubation medium and immediately recentrifuged.
Washed cells were disrupted by hypo-osmotic shock and rapid freezing followed by thawing, followed by addition of EDTA (10 mM) and membrane preparation as described above.
Radioligand binding experiments
All radioligand binding experiments were carried out in 96-well plates at 30 ºC in the incubation medium described above supplemented with freshly prepared dithiotreitol at a sec) using a hot plate. After cooling the filters were counted using a Wallac Microbeta scintillation counter.
Scintillation proximity assay
In case of scintillation proximity assay incubation with [ 35 S]GTPγS was terminated by membrane solubilization by the addition of 20 µl of 10% Nonidet P-40. After 20 min, 10 µl of individual primary antibodies against various G-protein alpha subunits were added and incubation was continued for 1 h. The final dilution was 1:1000 in case of anti-G ialpha and anti-G s -alpha antibodies and 1:2000 in case of the anti-G q -alpha antibody. One batch of anti-rabbit IgG-coated scintillation beads was diluted in 40 ml of incubation medium and 50 µl of the suspension was added to each well for 3 h. Then plates were centrifuged for 15 min at 1,000 x g and counted using the scintillation proximity assay protocol in a Wallac Microbeta scintillation counter.
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Analysis of the effects of xanomeline on the concentration-response curves to carbachol using Clark plots (Lew and Angus, 1996) pEC 50 = -log([x] + 10 -pKB ) -log c (Eq. 5) 
Results
Xanomeline
Kinetics of xanomeline wash-resistant activation of M 1 and M 2 receptors
In related experiments we explored possible differences in the rate of xanomeline washresistant activation of M 1 and M 2 receptors. Membranes were exposed to xanomeline for 
Interactions of xanomeline and carbachol in receptor activation
This article has not been copyedited and formatted. The final version may differ from this version. Effects of xanomeline on carbachol concentration-response curves were therefore analyzed by Clark's non-linear regression as described by Lew and Angus (1996) . In this analysis pEC 50 values obtained by fitting Eq. 4 to carbachol concentration-response curves in the presence of xanomeline (Fig. 5 , closed symbols and Table 1 ) were plotted against the logarithm of xanomeline concentration (Fig. 6 ) and Eq. 5 was fitted to the data. This analysis was applied to the data from individual experiments and means ± S.E.M. are shown in Table 2 . Estimates of the xanomeline equilibrium dissociation constant (K B ) in its continuous presence at both receptor subtypes are equal to the corresponding xanomeline concentration that produces half maximal receptor activation This article has not been copyedited and formatted. The final version may differ from this version. 
Activation of various G proteins by xanomeline and carbachol at M 1 and M 2 receptors.
Selectivity of xanomeline and carbachol in activating receptor coupling with various subtypes of G-proteins was studied using scintillation proximity assays. Figure 7 and Table 3 ).
Ratios of xanomeline to carbachol potencies also differed between M 1 and M 2 receptors.
While xanomeline present during 60 min preincubation was more than 140-times more potent than carbachol at the M 1 receptor in activating its principal G q subtype, it was only 35-times more potent at the M 2 receptor in activating its preferred G protein subtype, G i (Table 3) . Differences in potencies between xanomeline and carbachol at the remaining G-protein subtypes were much smaller, being only in the range of 3 to 8 times. These observations provide evidence that xanomeline is better than carbachol in discriminating among G-protein subtypes, and that this discrimination is more marked at the M 1 than at the M 2 receptor.
Wash resistant xanomeline binding at both receptors was accompanied by stimulation of stimulating G q at M 1 receptors and G i at M 2 receptors after washing were 88 and 79%, respectively, of levels observed after preincubation without washing. Furthermore, washing decreased efficacies of xanomeline for non-principal G-proteins to 68% (Gi) and 65% (Gs) at M 1 receptors but only to 73% (Gs) and 83% (Gq) at M 2 receptors compared to non-washing conditions (Table 3) . However, effects of washing were statistically significant only in the case of M 1 receptors.
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Discussion
Our data demonstrate that xanomeline binds to both the M 1 and M 2 subtypes of muscarinic acetylcholine receptors in a wash-resistant manner, albeit with an apparent lower potency than reversible binding. These observations confirm and complement previous reports demonstrating wash-resistant xanomeline binding at M 1 and M 5 muscarinic receptors, accompanied by persistent receptor activation and antagonism, respectively (Christopoulos et al., 1998; Grant and El-Fakahany, 2005) . We have previously provided experimental evidence that persistent attachment of xanomeline develops at receptor domains distinct from the classical orthosteric agonist binding site (Christopoulos et al., 1998 (Christopoulos et al., , 1999 Jakubik et al., 2002) , and depends on the length of Oalkyl side chain of xanomeline and the receptor lipid environment (Jakubik et al. 2004) .
In the present work we detected striking differences in the kinetics of xanomeline wash- We have also shown other important differences in the receptor agonistic effects of xanomeline and the conventional full agonist carbachol regarding effecting coupling of M 1 and M 2 receptors to various subtypes of G proteins. Namely, xanomeline is more selective in its efficacy than carbachol in favoring coupling of each receptor subtype to its preferred G protein (G q in case of M 1 and G i in case of M 2 ) in comparison to other G proteins (Table 3) . Xanomeline also exhibits a higher potency ratio than carbachol in activating preferred versus nonpreferred G-proteins. This indicator of xanomeline selectivity is more pronounced at M 1 than at M 2 receptors. In other words, xanomeline distinguishes between G-protein subtypes better than carbachol, with more discrimination at M 1 than at M 2 receptors. Distinction by xanomeline among different G proteins is maintained following washing of the free drug. Our observations support the existence of multiple active receptor conformations that differ in affinities for individual G-protein subtypes. Different agonists favor certain active receptor conformations over others. This is in agreement with the concept of agonist trafficking (Kenakin, 1995) .
This article has not been copyedited and formatted. The final version may differ from this version. In summary, xanomeline demonstrates marked selectivity in its binding kinetics and agonistic activity at M 1 and M 2 muscarinic receptors. The latter is evident in better ability of xanomeline than carbachol to differentiate between coupling of the receptor to various G proteins, both in terms of efficacy and potency. Such differences may work in concert to contribute to xanomeline's known functional selectivity towards M 1 over M 2 receptors (Wood et al., 1999) . Our data also add further support to the notion that xanomeline is Kenakin, 1995) .
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